Canaccord Genuity Downgrades Shockwave Medical to Hold, Raises Price Target to $335
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst William Plovanic downgraded Shockwave Medical (SWAV) from Buy to Hold but increased the price target from $263 to $335.

April 05, 2024 | 4:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Shockwave Medical was downgraded from Buy to Hold by Canaccord Genuity, although the price target was raised from $263 to $335.
The downgrade to Hold suggests a neutral outlook on the stock's short-term price movement, indicating that the analyst believes the stock might not provide significant upside from its current level. However, the increase in the price target to $335 reflects a positive view on the company's valuation and potential growth, which could counterbalance the downgrade's impact. Investors might see this as a signal that the stock is fairly valued at its current price, leading to a neutral short-term price direction.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100